The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts).
Luigi Rossi
No relevant relationships to disclose
Federica Tomao
No relevant relationships to disclose
Anselmo Papa
No relevant relationships to disclose
Federica Zoratto
No relevant relationships to disclose
Fabio Ricci
No relevant relationships to disclose
Gian Paolo Spinelli
No relevant relationships to disclose
Giuseppe Lo Russo
No relevant relationships to disclose
Enrico Basso
No relevant relationships to disclose
Giuliana Caprio
No relevant relationships to disclose
Simona Barberi
No relevant relationships to disclose
Monica Verrico
No relevant relationships to disclose
Erika Giordani
No relevant relationships to disclose
Eleonora Zaccarelli
No relevant relationships to disclose
Giulia Rinaldi
No relevant relationships to disclose
Valeria Stati
No relevant relationships to disclose
Giulia Pasciuti
No relevant relationships to disclose
Martina Strudel
No relevant relationships to disclose
Silverio Tomao
No relevant relationships to disclose